KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Cost of Revenue (2020 - 2025)

Esperion Therapeutics (ESPR) has disclosed Cost of Revenue for 6 consecutive years, with $41.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue rose 138.86% year-over-year to $41.3 million, compared with a TTM value of $127.0 million through Sep 2025, up 133.36%, and an annual FY2024 reading of $68.6 million, up 58.55% over the prior year.
  • Cost of Revenue was $41.3 million for Q3 2025 at Esperion Therapeutics, up from $28.5 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $41.3 million in Q3 2025 and bottomed at $1.8 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $13.4 million, with a median of $10.1 million recorded in 2024.
  • The sharpest move saw Cost of Revenue skyrocketed 5654.84% in 2021, then fell 26.05% in 2023.
  • Year by year, Cost of Revenue stood at $5.1 million in 2021, then decreased by 18.03% to $4.2 million in 2022, then skyrocketed by 175.29% to $11.5 million in 2023, then soared by 123.81% to $25.6 million in 2024, then surged by 61.09% to $41.3 million in 2025.
  • Business Quant data shows Cost of Revenue for ESPR at $41.3 million in Q3 2025, $28.5 million in Q2 2025, and $31.5 million in Q1 2025.